» Articles » PMID: 17151112

Synergistic Attenuation of Vesicular Stomatitis Virus by Combination of Specific G Gene Truncations and N Gene Translocations

Overview
Journal J Virol
Date 2006 Dec 8
PMID 17151112
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

A variety of rational approaches to attenuate growth and virulence of vesicular stomatitis virus (VSV) have been described previously. These include gene shuffling, truncation of the cytoplasmic tail of the G protein, and generation of noncytopathic M gene mutants. When separately introduced into recombinant VSV (rVSV), these mutations gave rise to viruses distinguished from their "wild-type" progenitor by diminished reproductive capacity in cell culture and/or reduced cytopathology and decreased pathogenicity in vivo. However, histopathology data from an exploratory nonhuman primate neurovirulence study indicated that some of these attenuated viruses could still cause significant levels of neurological injury. In this study, additional attenuated rVSV variants were generated by combination of the above-named three distinct classes of mutation. The resulting combination mutants were characterized by plaque size and growth kinetics in cell culture, and virulence was assessed by determination of the intracranial (IC) 50% lethal dose (LD(50)) in mice. Compared to virus having only one type of attenuating mutation, all of the mutation combinations examined gave rise to virus with smaller plaque phenotypes, delayed growth kinetics, and 10- to 500-fold-lower peak titers in cell culture. A similar pattern of attenuation was also observed following IC inoculation of mice, where differences in LD(50) of many orders of magnitude between viruses containing one and two types of attenuating mutation were sometimes seen. The results show synergistic rather than cumulative increases in attenuation and demonstrate a new approach to the attenuation of VSV and possibly other viruses.

Citing Articles

Development of Long-Term Stability of Enveloped rVSV Viral Vector Expressing SARS-CoV-2 Antigen Using a DOE-Guided Approach.

Khan M, Wagner C, Kamen A Vaccines (Basel). 2024; 12(11).

PMID: 39591143 PMC: 11598241. DOI: 10.3390/vaccines12111240.


Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus.

Matassov D, DeWald L, Hamm S, Nowak R, Gerardi C, Latham T Vaccines (Basel). 2024; 12(8).

PMID: 39203984 PMC: 11358935. DOI: 10.3390/vaccines12080858.


Regulated control of virus replication by 4-hydroxytamoxifen-induced splicing.

Zhao Z, Wang B, Wu S, Zhang Z, Chen Y, Zhang J Front Microbiol. 2023; 14:1112580.

PMID: 36992923 PMC: 10040539. DOI: 10.3389/fmicb.2023.1112580.


Replicating-Competent VSV-Vectored Pseudotyped Viruses.

Yuan F, Zheng A Adv Exp Med Biol. 2023; 1407:329-348.

PMID: 36920706 DOI: 10.1007/978-981-99-0113-5_18.


Quantification of in vitro replication kinetics of Alagoas vesiculovirus isolates by digital droplet RT-PCR.

Sales M, Fonseca Junior A, Pinheiro de Oliveira T, de Araujo Lopes A, Rivetti Junior A, Camargos M Braz J Microbiol. 2023; 54(1):491-497.

PMID: 36645640 PMC: 9841932. DOI: 10.1007/s42770-023-00902-w.


References
1.
Haglund K, Forman J, Krausslich H, Rose J . Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology. 2000; 268(1):112-21. DOI: 10.1006/viro.1999.0120. View

2.
Kahn J, Schnell M, Buonocore L, Rose J . Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology. 1999; 254(1):81-91. DOI: 10.1006/viro.1998.9535. View

3.
Baltimore D, Huang A, Stampfer M . Ribonucleic acid synthesis of vesicular stomatitis virus, II. An RNA polymerase in the virion. Proc Natl Acad Sci U S A. 1970; 66(2):572-6. PMC: 283083. DOI: 10.1073/pnas.66.2.572. View

4.
Whelan S, Ball L, Barr J, Wertz G . Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A. 1995; 92(18):8388-92. PMC: 41162. DOI: 10.1073/pnas.92.18.8388. View

5.
Colasanti M, Persichini T, Venturini G, Ascenzi P . S-nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide. IUBMB Life. 2000; 48(1):25-31. DOI: 10.1080/713803459. View